Skip To Main Content

Áreas terapeúticas

Descubra la más reciente actualización sobre la evidencia científica y los datos basados en la vida real que se han recopilado en el campo de la epidemiología. Esta información incluye detalles sobre la carga que estas enfermedades imponen a las personas y a la sociedad en general, así como los métodos de control que se están implementando para hacer frente a estas situaciones.

También se aborda el impacto económico que tienen enfermedades como asma grave, cardiovascular, dermatitis atópica, diabetes o enfermedades raras, etc., en la vida de nuestra población. Estos elementos son fundamentales para comprender la magnitud del problema y para desarrollar estrategias efectivas que ayuden a mejorar la salud pública.

Ordenar por

Patología

Limpiar filtro
  • Filtros
Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

IMD: Why Every Hour Matters in Meningococcal Disease Management

IMD: Why Every Hour Matters in Meningococcal Disease Management

Learn about the rapid progression of Invasive Meningococcal Disease (IMD), its clinical manifestations, and why early diagnosis is crucial for patient survival.

IMD Complications & Family Burden: Understanding the Multi-dimensional Impact

IMD Complications & Family Burden: Understanding the Multi-dimensional Impact

Explore the comprehensive impact of Invasive Meningococcal Disease (IMD), including family burden, survivor complications, and quality of life effects. Learn about neurological and non-neurological complications affecting IMD survivors.

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

 Nuevas Fronteras en Diabetes Tipo 1

Nuevas Fronteras en Diabetes Tipo 1

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024